The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Tuesday, KeyBanc reaffirmed its Overweight rating and $12.00 price target for Recursion Pharmaceuticals (NASDAQ:RXRX), following the announcement of Phase 2 trial results for REC-994. The ...
The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31, ...
On Wednesday, KeyBanc Capital Markets maintained its Overweight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) with a steady price target of $12.00. The affirmation follows Recursion's recent ...
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results